Russian drugs with precise delivery system may become available in five years

20 July 2018

GMP News

A system of intracellular drug delivery was developed at the Institute of Theoretical and Experimental Biophysics (ITEB) of The Russian Academy of Sciences (RAS). This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

Anton Popov, a researcher at the Institute, said that their team had developed a new system for intracellular delivery of biologically active substances based on polyelectrolyte microcapsules. They include cerium dioxide nanoparticles, which can be used to create a new generation of anti-inflammatory drugs.

This type of nanoparticles has unique antioxidant properties that neutralize the reactive oxygen intermediates harmful to cells. Nanoparticles form a thin layer in the shell of designed microcapsule. This protects the substance from exposure to aggressive environmental factors.

Such microcontainers (polyelectrolyte microcapsules) have been known for a long time and are well-studied as a system to deliver substances, including various medicines, into the cell. According to Vladimir Chubarev, Professor of Pharmacology Department at the Institute of Pharmacy and Translational Medicine of I.M. Sechenov Moscow State Medical University, the development of the first drugs in the form of microcapsules began in Russia almost a half century ago.

“Our Institute developed the theoretical platform for creating microcapsules based on liposomes. Later, they found their practical application as liposomal drugs containing various medicinal substances. The study of pharmacological properties of these microcapsules demonstrated very interesting results. Microcapsules use leads to significant improvement in bioavailability of drugs, allowing dose reduction and thus, reduction of side effects,” said Vladimir Chubarev.

According to the scientist, new Russian medicines in the form of microcapsules will be available in the market within five years.

Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more